Skip to content

Kura Oncology KURA Book value per share

Book value per share at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$33.20+3.0%
Amgen logo
AmgenAMGN
$16.89+47.2%
Exelixis logo
ExelixisEXEL
$7.24-2.1%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$0.47-81.1%
AbbVie logo
AbbVieABBV
-$3.75-568%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$2.67+307%

Other financials

Income statement

See full
Revenue$18.3M+29.5%
Gross profit$18.0M
Operating income-$78.8M-21.8%
Net income-$73.3M-27.7%
EPS (diluted)-$0.83-25.8%

Balance sheet

See full
Cash & equivalents$39.1M-23.8%
Total debt$24.3M+25.4%
Total equity$107.9M-70.4%
Total assets$652.6M-12.3%

Cash flow

See full
Operating cash flow-$85.9M-19.4%
CapEx$128.0K-56.2%
Free cash flow-$86.0M-19.1%

Valuation

See full
Market cap$942.78M+86.2%
Enterprise value$927.97M+95.5%
P/S13.2×+3.9×

Profitability

See full
Operating margin-443.5%+103pp
Net margin-411.2%+125pp
FCF margin130.6%+74.1pp

Returns & leverage

See full
Return on equity-124.7%-252pp
Debt / equity0.2×+0.2×
Current ratio6.1×-1.9×

Where this comes from

Calculated from Kura Oncology’s reported figures.

Based on the most recent quarter.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kura Oncology's book value per share?
Kura Oncology (KURA) reported book value per share of $1.22 in Q1 2026.
How has Kura Oncology's book value per share changed year-over-year?
Kura Oncology's book value per share decreased by 70.8% year-over-year, from $4.17 to $1.22.
What is the long-term trend for Kura Oncology's book value per share?
Over 5 years (2020 to 2025), Kura Oncology's book value per share has grown at a -29.6% compound annual growth rate (CAGR), from $11.51 to $1.99.
What does book value per share mean?
Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.